Meredith Fisher, PhD, is a Partner with Mass General Brigham Ventures, where she focuses on early-stage investments and company creation. Previously, she was director of private investments in the private/family office at Bracebridge Capital, where she led investments in early-stage life science companies. She previously led business development for Ginkgo BioWorks, was senior director at PureTech Ventures, and was a scientist in anti-viral drug discovery for Idenix Pharmaceuticals and Anadys Pharmaceuticals.
Meredith currently holds board seats at BraveBio, ClarisBio, FireCyte, Mediar Therapeutics, Nocion Therapeutics, Violet, and ZielBio and serves as a board observer for Scorpion Therapeutics and Amolyt.
Meredith holds an undergraduate degree from Mount Holyoke College, an MBA from the MIT Sloan School of Management, and a PhD from Harvard University. While at Harvard, she co-founded Harvard Graduate Women in Science and Engineering (HGWISE).